Brian Hotchkiss is the Chief Business Officer of Bexorg, a Yale University spinout building the first integrated AI and whole-human-brain platform for central nervous system drug discovery. A chemical engineer turned biotech dealmaker, he spent nearly seven years at Stealth BioTherapeutics shaping corporate strategy and helping land a transformative Alexion collaboration, then served as Chief Business Officer at Protego Biopharma before joining Bexorg. He pairs four graduate-level degrees in engineering, biology, and business with a career spent translating hard science into partnerships, capital, and commercial strategy.
Sheldon J.J. Kwok is the CEO and co-founder of LASE Innovation, a Boston-area techbio company turning microscopic lasers into cellular barcodes. He spent his PhD at MIT and Massachusetts General Hospital building particles that emit pure laser light from inside living cells, then spun the work into a company aiming to give every cell a trackable identity and add a time dimension to flow cytometry.
Steve Worland, Ph.D., is the CEO of Numerion Labs, the AI-native drug discovery company that grew out of Atomwise. A medicinal-chemistry lifer with three decades behind him, his bench work fed the discovery of Paxlovid and Inlyta, and his operating record runs from Agouron through a Roche acquisition to a SPAC. Now he is betting that deep-learning surrogates plus GPU enumeration can search billions of molecules in seconds.
Elucidata is a TechBio company building Polly, a data-centric ML-Ops platform that harmonizes messy biomedical data into AI-ready datasets for pharma R&D. Founded in 2015 by Abhishek Jha and Swetabh Pathak, the company powers drug discovery work at Pfizer, Genentech, Janssen and dozens of biotechs from offices in San Francisco, Boston and Delhi.
insitro is a machine-learning-driven drug discovery and development company that uses high-content human data, cellular models and AI to find better targets and design better medicines. Founded in 2018 by Daphne Koller, the company runs its own therapeutic pipeline and partners with large pharma on programs in ALS, metabolic disease and oncology.
Stuart Peterson is the Founder and Managing General Partner of ARTIS Ventures, a San Francisco-based venture capital firm he launched in 2001 that coined and trademarked the term 'TechBio.' A 2017 Forbes Midas List honoree, Peterson led early-stage investments in YouTube (acquired by Google) and StemCentrx (acquired by AbbVie for $10.2 billion - the largest-ever venture-backed life sciences acquisition), and has since focused ARTIS at the convergence of computer science and life science, closing a $200 million TechBio II Fund in December 2023 to back next-generation health and medicine companies deploying AI, machine learning, and deep learning to transform human health.
Omri Amirav-Drory, Ph.D., is a General Partner at NFX leading NFX Bio, a pre-seed and seed venture fund focused on scientist-founders at the intersection of technology and biology. A former Fulbright Scholar and Stanford postdoc turned biotech entrepreneur, he co-founded Genome Compiler (acquired by Twist Bioscience), launched Tech.Bio, and now backs breakthrough life sciences companies while co-founding Renewal Bio - a longevity company building synthetic embryo-derived tissues to combat aging. His stated mission is ending involuntary death.